pCDCAR1 NKG2DL h(ζ) (CAR-MZ231)

The vector of NKG2D based chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human NKG2D ligands. The NK cells are genetically modified through transduction with a retroviral vector expressing NKG2D receptor linked to CD3ζ signaling domains. And the vector product was designed for the treatment of human ovarian cancer.

Datasheet   Add to Cart


  • Target
  • NKG2D ligands
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • Human ovarian cancer
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Retroviral
  • Receptor Construction
  • NKG2D receptor-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.


  • Target Species
  • Human
  • Gene Name
  • NKG2D ligands
  • Synonyms
  • NKG2D ligands

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.